RespireRx Pharmaceuticals Inc.
RSPI
$0.0021
$0.0011110.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 41.92% | -58.34% | -48.46% | 38.70% | 1.60% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 2,677.78% | -30.77% | -23.53% | -81.36% | -64.09% |
| Total Other Non-Cash Items | 16.83% | 63.41% | -115.63% | 2,062.22% | 82.59% |
| Change in Net Operating Assets | -68.12% | 32.26% | 264.65% | -68.39% | 6.67% |
| Cash from Operations | 21.46% | -340.41% | -360.71% | 116.02% | -12.74% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -100.00% | 125.34% | 247.62% | -92.32% | 11.63% |
| Total Debt Repaid | -- | -- | -- | 48.55% | -0.26% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 42.86% | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -200.00% |
| Cash from Financing | -26.36% | 365.07% | 363.06% | -115.86% | 13.27% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -113.89% | 7,100.00% | -- | -- | 100.00% |